Supplementary Materials

Supplementary Material for:

FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection

Lisa M. Johansen,* Jennifer M. Brannan, Sue E. Delos, Charles J. Shoemaker, Andrea Stossel, Calli Lear, Benjamin G. Hoffstrom, Lisa Evans DeWald, Kathryn L. Schornberg, Corinne Scully, Joseph Lehár, Lisa E. Hensley, Judith M. White, Gene G. Olinger*

*Corresponding author. E-mail: gene.olinger@us.army.mil (G.G.O.); ljohansen@zalicus.com (L.M.J.)

Published 19 June 2013, Sci. Transl. Med. 5, 190ra79 (2013)
DOI: 10.1126/scitranslmed.3005471

This PDF file includes:

  • Fig. S1. SERMS inhibit EBOV infection in vitro.
  • Fig. S2. The activity of clomiphene and toremifene against native strains of filoviruses using qRT-PCR.
  • Fig. S3. Kaplan-Meier survival curves for clomiphene in both male and female mice infected with a mouse-adapted Ebola virus.
  • Fig. S4. Western blot analysis showing ER-α and ER-β expression in cell line panel.
  • Fig. S5. Activity of clomiphene and toremifene in HUVECs.
  • Fig. S6. Representative flow cytometry plots from experiments conducted for Fig. 6.
  • Fig. S7. Effect of clomiphene and toremifene treatment on entry of VLPs bearing GP from SUDV.
  • Fig. S8. Cathepsin L processing at 18 hours.

[Download PDF]